JP2014531469A - Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 - Google Patents

Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 Download PDF

Info

Publication number
JP2014531469A
JP2014531469A JP2014534641A JP2014534641A JP2014531469A JP 2014531469 A JP2014531469 A JP 2014531469A JP 2014534641 A JP2014534641 A JP 2014534641A JP 2014534641 A JP2014534641 A JP 2014534641A JP 2014531469 A JP2014531469 A JP 2014531469A
Authority
JP
Japan
Prior art keywords
aeeac
shk toxin
added
pmp
shk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014534641A
Other languages
English (en)
Japanese (ja)
Inventor
チャンディ、ケイ．ジョージ
ク アパダヤイ、サンジーブ
クマール アパダヤイ、サンジーブ
エイチ． ワン、ピン
サスーン−コルシ、パオロ
リン エッケル−メーハン、クリスティン
イアドネート、ショーン
ムケルジー、ジョゲシュ
ミアボロッキィ、エム．レザ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Kv1.3 Therapeutics Inc
Original Assignee
University of California
Kineta One LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Kineta One LLC filed Critical University of California
Publication of JP2014531469A publication Critical patent/JP2014531469A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014534641A 2011-10-03 2012-10-02 Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 Pending JP2014531469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
US61/542,751 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
JP2014531469A true JP2014531469A (ja) 2014-11-27

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534641A Pending JP2014531469A (ja) 2011-10-03 2012-10-02 Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療

Country Status (16)

Country Link
US (2) US20150072940A1 (enExample)
EP (1) EP2763702A4 (enExample)
JP (1) JP2014531469A (enExample)
KR (1) KR20140108518A (enExample)
CN (1) CN103987408A (enExample)
AU (1) AU2012318736A1 (enExample)
BR (1) BR112014008065A2 (enExample)
CA (1) CA2850357A1 (enExample)
HK (1) HK1201048A1 (enExample)
IL (1) IL231873A0 (enExample)
IN (1) IN2014CN03333A (enExample)
MX (1) MX2014004029A (enExample)
RU (1) RU2014117558A (enExample)
SG (1) SG11201401193XA (enExample)
TW (1) TW201321403A (enExample)
WO (1) WO2013052507A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5118969B2 (ja) * 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
TW201542231A (zh) 2011-06-06 2015-11-16 Kineta One Llc 以ｓｈｋ為主之醫藥組合物及其製備方法及用途
US20150072940A1 (en) 2011-10-03 2015-03-12 Kineta One, Llc Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels
US10265384B2 (en) * 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
WO1998023639A2 (en) 1996-11-27 1998-06-04 University Of Florida ShK TOXIN COMPOSITIONS AND METHODS OF USE
WO1999013895A1 (en) * 1997-09-17 1999-03-25 University Of Florida Polypeptide compositions that inhibit potassium channel activity and uses therefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
JP5118969B2 (ja) 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2006281368A1 (en) * 2005-08-17 2007-02-22 Solvay Pharmaceuticals Gmbh Method of using potassium channel inhibiting compounds
AR074558A1 (es) * 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
US20150072940A1 (en) 2011-10-03 2015-03-12 Kineta One, Llc Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels

Also Published As

Publication number Publication date
EP2763702A1 (en) 2014-08-13
CA2850357A1 (en) 2013-04-11
WO2013052507A1 (en) 2013-04-11
US9878006B2 (en) 2018-01-30
HK1201048A1 (en) 2015-08-21
BR112014008065A2 (pt) 2019-09-24
CN103987408A (zh) 2014-08-13
KR20140108518A (ko) 2014-09-11
US20170095530A1 (en) 2017-04-06
IL231873A0 (en) 2014-05-28
RU2014117558A (ru) 2015-11-10
AU2012318736A1 (en) 2014-05-22
IN2014CN03333A (enExample) 2015-07-03
TW201321403A (zh) 2013-06-01
MX2014004029A (es) 2014-08-01
SG11201401193XA (en) 2014-05-29
US20150072940A1 (en) 2015-03-12
EP2763702A4 (en) 2015-04-15

Similar Documents

Publication Publication Date Title
JP7094327B2 (ja) 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物
ES2502218T3 (es) Análogos de glucagón
TWI670281B (zh) Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
JP5820349B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
TWI608013B (zh) 升糖素類似物
TWI642682B (zh) 升糖素類似物
US9878006B2 (en) Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
JP5743371B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
WO2020023386A1 (en) Gip/glp1 co-agonist compounds
JP2013545782A (ja) 長時間作用型インスリンと組み合わせた速効型インスリン
CN115124602B (zh) Gip和glp-1的双受体激动剂、药物组合物及用途
SG185066A1 (en) Glucagon-like peptide-1 analogue and use thereof
CA3073011A1 (en) Acylated oxyntomodulin peptide analog
US20160228563A1 (en) Lipidated peptides for lowering blood glucose
WO2016168388A2 (en) Therapies for obesity, diabetes and related indications
KR20150070180A (ko) 근위축성 측삭 경화증 치료제
Irwin et al. Evaluation of the long-term effects of gastric inhibitory polypeptide–ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice
TW202535452A (zh) 治療青少年肥胖症的方法
WO2024067662A1 (zh) Glp-1/gcg/gip三受体激动剂及其用途
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
CA3166027A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
US20150197550A1 (en) Therapeutic Uses of Dogfish Glucagon and Analogues Thereof